Interruption of the OX40-OX40 ligand pathway in LDL receptor-deficient mice causes regression of atherosclerosis

Journal of Immunology

Volumn 191, Issue 9, 2013, Pages 4573-4580

  Foks, Amanda C ^a   Van Puijvelde, Gijs H M ^a   Bot, Ilze ^a   Ter Borg, Mariette N D ^a   Habets, Kim L L ^a   Johnson, Jason L ^b   Yagita, Hideo ^c   Van Berkel, Theo J C ^a   Kuiper, Johan ^a  

^a LEIDEN UNIVERSITY   (Netherlands)

^b BRISTOL ROYAL INFIRMARY   (United Kingdom)

^c JUNTENDO UNIVERSITY   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

CHOLESTEROL; IMMUNOGLOBULIN E; IMMUNOGLOBULIN M; INTERLEUKIN 4; INTERLEUKIN 5; LOW DENSITY LIPOPROTEIN RECEPTOR; OX40 LIGAND; TRANSCRIPTION FACTOR GATA 3; CD134 ANTIGEN; GATA3 PROTEIN, MOUSE; INTERLEUKIN DERIVATIVE; INTERLEUKIN-33, MOUSE; MEMBRANE PROTEIN; MONOCLONAL ANTIBODY; TNFRSF4 PROTEIN, MOUSE; TNFSF4 PROTEIN, MOUSE; TUMOR NECROSIS FACTOR;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; AORTA ARCH; AORTA ATHEROSCLEROSIS; ARTICLE; B LYMPHOCYTE; CELL ACTIVATION; CELLULAR IMMUNITY; CONTROLLED STUDY; CYTOKINE PRODUCTION; DOWN REGULATION; IMMUNOGLOBULIN PRODUCTION; MALE; MAST CELL; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN PROTEIN INTERACTION; SIGNAL TRANSDUCTION; T LYMPHOCYTE; TH2 CELL; UPREGULATION; ANIMAL; ANTIGEN PRESENTING CELL; ATHEROSCLEROSIS; BIOSYNTHESIS; BLOOD; C57BL MOUSE; CELL CULTURE; CELL PROLIFERATION; DEFICIENCY; GENETICS; IMMUNOLOGY; KNOCKOUT MOUSE; LYMPHOCYTE ACTIVATION; METABOLISM;

ANIMALS; ANTIBODIES, MONOCLONAL; ANTIGEN-PRESENTING CELLS; ATHEROSCLEROSIS; CELL PROLIFERATION; CELLS, CULTURED; CHOLESTEROL; GATA3 TRANSCRIPTION FACTOR; IMMUNOGLOBULIN E; IMMUNOGLOBULIN M; INTERLEUKIN-4; INTERLEUKIN-5; INTERLEUKINS; LYMPHOCYTE ACTIVATION; MALE; MAST CELLS; MEMBRANE GLYCOPROTEINS; MICE; MICE, INBRED C57BL; MICE, KNOCKOUT; RECEPTORS, LDL; RECEPTORS, OX40; TH2 CELLS; TUMOR NECROSIS FACTORS;

EID: 84886026214     PISSN: 00221767     EISSN: 15506606     Source Type: Journal    
DOI: 10.4049/jimmunol.1200708     Document Type: Article

References (49)

1. Nissen, S. E. 2005. Effect of intensive lipid lowering on progression of coronary atherosclerosis: evidence for an early benefit from the Reversal of Atherosclerosis with Aggressive Lipid Lowering (REVERSAL) trial. Am. J. Cardiol. 96 (5A): 61F-68F.
2. Nissen, S. E., S. J. Nicholls, I. Sipahi, P. Libby, J. S. Raichlen, C. M. Ballantyne, J. Davignon, R. Erbel, J. C. Fruchart, J. C. Tardif, et al; ASTEROID Investigators. 2006. Effect of very high-intensity statin therapy on regression of coronary atherosclerosis: the ASTEROID trial. JAMA 295: 1556-1565.
3. Desurmont, C., J. M. Caillaud, F. Emmanuel, P. Benoit, J. C. Fruchart, G. Castro, D. Branellec, J. M. Heard, and N. Duverger. 2000. Complete atherosclerosis regression after human ApoE gene transfer in ApoE-deficient/nude mice. Arterioscler. Thromb. Vasc. Biol. 20: 435-442.
4. Harris, J. D., S. Schepelmann, T. Athanasopoulos, I. R. Graham, A. K. Stannard, Z. Mohri, V. Hill, D. G. Hassall, J. S. Owen, and G. Dickson. 2002. Inhibition of atherosclerosis in apolipoprotein-E-deficient mice following muscle transduction with adeno-associated virus vectors encoding human apolipoprotein-E. Gene Ther. 9: 21-29.
5. Verschuren, L., J. de Vries-van der Weij, S. Zadelaar, R. Kleemann, and T. Kooistra. 2009. LXR agonist suppresses atherosclerotic lesion growth and promotes lesion regression in apoE3Leiden mice: time course and mechanisms. J. Lipid Res. 50: 301-311.
6. Feig, J. E., I. Pineda-Torra, M. Sanson, M. N. Bradley, Y. Vengrenyuk, D. Bogunovic, E. L. Gautier, D. Rubinstein, C. Hong, J. Liu, et al. 2010. LXR promotes the maximal egress of monocyte-derived cells from mouse aortic plaques during atherosclerosis regression. J. Clin. Invest. 120: 4415-4424.
7. -/- mice during disease regression. J. Clin. Invest. 121: 2025-2036.
8. Hansson, G. K., and P. Libby. 2006. The immune response in atherosclerosis: a double-edged sword. Nat. Rev. Immunol. 6: 508-519.
9. -/- mice. J. Am. Coll. Cardiol. 50: 2313-2318.
10. Arestides, R. S., H. He, R. M. Westlake, A. I. Chen, A. H. Sharpe, D. L. Perkins, and P. W. Finn. 2002. Costimulatory molecule OX40L is critical for both Th1 and Th2 responses in allergic inflammation. Eur. J. Immunol. 32: 2874-2880.
11. Stüber, E., and W. Strober. 1996. The T cell-B cell interaction via OX40-OX40L is necessary for the T cell-dependent humoral immune response. J. Exp. Med. 183: 979-989.
12. Weinberg, A. D., K. W. Wegmann, C. Funatake, and R. H. Whitham. 1999. Blocking OX-40/OX-40 ligand interaction in vitro and in vivo leads to decreased T cell function and amelioration of experimental allergic encephalomyelitis. J. Immunol. 162: 1818-1826.
13. +) T cells with chronic graft-versus-host disease in patients who underwent allogeneic hematopoietic stem cell transplantation. Blood 98: 3162-3164.
14. Yoshioka, T., A. Nakajima, H. Akiba, T. Ishiwata, G. Asano, S. Yoshino, H. Yagita, and K. Okumura. 2000. Contribution of OX40/OX40 ligand interaction to the pathogenesis of rheumatoid arthritis. Eur. J. Immunol. 30: 2815-2823.
15. van Wanrooij, E. J., G. H. van Puijvelde, P. de Vos, H. Yagita, T. J. van Berkel, and J. Kuiper. 2007. Interruption of the Tnfrsf4/Tnfsf4 (OX40/OX40L) pathway attenuates atherogenesis in low-density lipoprotein receptor-deficient mice. Arterioscler. Thromb. Vasc. Biol. 27: 204-210.
16. Nakano, M., Y. Fukumoto, K. Satoh, Y. Ito, Y. Kagaya, N. Ishii, K. Sugamura, and H. Shimokawa. 2010. OX40 ligand plays an important role in the development of atherosclerosis through vasa vasorum neovascularization. Cardiovasc. Res. 88: 539-546.
17. Wang, X., M. Ria, P. M. Kelmenson, P. Eriksson, D. C. Higgins, A. Samnegård, C. Petros, J. Rollins, A. M. Bennet, B. Wiman, et al. 2005. Positional identification of TNFSF4, encoding OX40 ligand, as a gene that influences atherosclerosis susceptibility. Nat. Genet. 37: 365-372.
18. Paigen, B., D. Mitchell, K. Reue, A. Morrow, A. J. Lusis, and R. C. LeBoeuf. 1987. Ath-1, a gene determining atherosclerosis susceptibility and high density lipoprotein levels in mice. Proc. Natl. Acad. Sci. USA 84: 3763-3767.
19. Ria, M., P. Eriksson, S. Boquist, C. G. Ericsson, A. Hamsten, and J. Lagercrantz. 2006. Human genetic evidence that OX40 is implicated in myocardial infarction. Biochem. Biophys. Res. Commun. 339: 1001-1006.
20. Olofsson, P. S., L. A. Söderström, C. Jern, A. Sirsjö, M. Ria, E. Sundler, U. de Faire, P. G. Wiklund, J. Ohrvik, U. Hedin, et al. 2009. Genetic variants of TNFSF4 and risk for carotid artery disease and stroke. J. Mol. Med. 87: 337-346.
21. Huang, W. C., G. B. Sala-Newby, A. Susana, J. L. Johnson, and A. C. Newby. 2012. Classical macrophage activation up-regulates several matrix metalloproteinases through mitogen activated protein kinases and nuclear factor-κB. PLoS ONE 7: e42507.
22. + T cells blocks their inhibitory activity: a novel regulatory role for OX40 and its comparison with GITR. Blood 105: 2845-2851.
23. Binder, C. J., K. Hartvigsen, M. K. Chang, M. Miller, D. Broide, W. Palinski, L. K. Curtiss, M. Corr, and J. L. Witztum. 2004. IL-5 links adaptive and natural immunity specific for epitopes of oxidized LDL and protects from atherosclerosis. J. Clin. Invest. 114: 427-437.
24. Sämpi, M., O. Ukkola, M. Päivänsalo, Y. A. Kesäniemi, C. J. Binder, and S. Hörkkö. 2008. Plasma interleukin-5 levels are related to antibodies binding to oxidized low-density lipoprotein and to decreased subclinical atherosclerosis. J. Am. Coll. Cardiol. 52: 1370-1378.
25. + T cells and promotes allergic-induced airway inflammation independent of IL-4. J. Immunol. 181: 4780-4790.
26. Schmitz, J., A. Owyang, E. Oldham, Y. Song, E. Murphy, T. K. McClanahan, G. Zurawski, M. Moshrefi, J. Qin, X. Li, et al. 2005. IL-33, an interleukin-1-like cytokine that signals via the IL-1 receptor-related protein ST2 and induces T helper type 2-associated cytokines. Immunity 23: 479-490.
27. Yamaguchi, Y., T. Suda, J. Suda, M. Eguchi, Y. Miura, N. Harada, A. Tominaga, and K. Takatsu. 1988. Purified interleukin 5 supports the terminal differentiation and proliferation of murine eosinophilic precursors. J. Exp. Med. 167: 43-56.
28. Tardif, J. C., J. Grégoire, P. L. L'Allier, R. Ibrahim, J. Lespérance, T. M. Heinonen, S. Kouz, C. Berry, R. Basser, M. A. Lavoie, et al.; Effect of rHDL on Atherosclerosis-Safety and Efficacy (ERASE) Investigators. 2007. Effects of reconstituted high-density lipoprotein infusions on coronary atherosclerosis: a randomized controlled trial. JAMA 297: 1675-1682.
29. Nissen, S. E., J. C. Tardif, S. J. Nicholls, J. H. Revkin, C. L. Shear, W. T. Duggan, W. Ruzyllo, W. B. Bachinsky, G. P. Lasala, and E. M. Tuzcu; ILLUSTRATE Investigators. 2007. Effect of torcetrapib on the progression of coronary atherosclerosis. N. Engl. J. Med. 356: 1304-1316.
30. Rayner, K. J., F. J. Sheedy, C. C. Esau, F. N. Hussain, R. E. Temel, S. Parathath, J. M. van Gils, A. J. Rayner, A. N. Chang, Y. Suarez, et al. 2011. Antagonism of miR-33 in mice promotes reverse cholesterol transport and regression of atherosclerosis. J. Clin. Invest. 121: 2921-2931.
31. Daoud, A. S., J. Jarmolych, J. M. Augustyn, and K. E. Fritz. 1981. Sequential morphologic studies of regression of advanced atherosclerosis. Arch. Pathol. Lab. Med. 105: 233-239.
32. Shimoda, K., J. van Deursen, M. Y. Sangster, S. R. Sarawar, R. T. Carson, R. A. Tripp, C. Chu, F. W. Quelle, T. Nosaka, D. A. Vignali, et al. 1996. Lack of IL-4-induced Th2 response and IgE class switching in mice with disrupted Stat6 gene. Nature 380: 630-633.
33. Zheng, W., and R. A. Flavell. 1997. The transcription factor GATA-3 is necessary and sufficient for Th2 cytokine gene expression in CD4 T cells. Cell 89: 587-596.
34. Miller, A. M., D. Xu, D. L. Asquith, L. Denby, Y. Li, N. Sattar, A. H. Baker, I. B. McInnes, and F. Y. Liew. 2008. IL-33 reduces the development of atherosclerosis. J. Exp. Med. 205: 339-346.
35. McLaren, J. E., D. R. Michael, R. C. Salter, T. G. Ashlin, C. J. Calder, A. M. Miller, F. Y. Liew, and D. P. Ramji. 2010. IL-33 reduces macrophage foam cell formation. J. Immunol. 185: 1222-1229.
36. Miller, A. M., D. L. Asquith, A. J. Hueber, L. A. Anderson, W. M. Holmes, A. N. McKenzie, D. Xu, N. Sattar, I. B. McInnes, and F. Y. Liew. 2010. Interleukin-33 induces protective effects in adipose tissue inflammation during obesity in mice. Circ. Res. 107: 650-658.
37. Moussion, C., N. Ortega, and J. P. Girard. 2008. The IL-1-like cytokine IL-33 is constitutively expressed in the nucleus of endothelial cells and epithelial cells in vivo: a novel "alarmin"? PLoS ONE 3: e3331.
38. Watts, T. H., and M. A. DeBenedette. 1999. T cell co-stimulatory molecules other than CD28. Curr. Opin. Immunol. 11: 286-293.
39. Binder, C. J., P. X. Shaw, M. K. Chang, A. Boullier, K. Hartvigsen, S. Hörkkö, Y. I. Miller, D. A. Woelkers, M. Corr, and J. L. Witztum. 2005. The role of natural antibodies in atherogenesis. J. Lipid Res. 46: 1353-1363.
40. Chang, M. K., C. J. Binder, Y. I. Miller, G. Subbanagounder, G. J. Silverman, J. A. Berliner, and J. L. Witztum. 2004. Apoptotic cells with oxidation-specific epitopes are immunogenic and proinflammatory. J. Exp. Med. 200: 1359-1370.
41. Akiba, H., Y. Miyahira, M. Atsuta, K. Takeda, C. Nohara, T. Futagawa, H. Matsuda, T. Aoki, H. Yagita, and K. Okumura. 2000. Critical contribution of OX40 ligand to T helper cell type 2 differentiation in experimental leishmaniasis. J. Exp. Med. 191: 375-380.
42. MacPhee, I. A., H. Yagita, and D. B. Oliveira. 2006. Blockade of OX40-ligand after initial triggering of the T helper 2 response inhibits mercuric chlorideinduced autoimmunity. Immunology 117: 402-408.
43. Laine, P., M. Kaartinen, A. Penttilä, P. Panula, T. Paavonen, and P. T. Kovanen. 1999. Association between myocardial infarction and the mast cells in the adventitia of the infarct-related coronary artery. Circulation 99: 361-369.
44. Chaldakov, G. N., I. S. Stankulov, M. Fiore, P. I. Ghenev, and L. Aloe. 2001. Nerve growth factor levels and mast cell distribution in human coronary atherosclerosis. Atherosclerosis 159: 57-66.
45. Bot, I., S. C. de Jager, A. Zernecke, K. A. Lindstedt, T. J. van Berkel, C. Weber, and E. A. Biessen. 2007. Perivascular mast cells promote atherogenesis and induce plaque destabilization in apolipoprotein E-deficient mice. Circulation 115: 2516-2525.
46. Nakae, S., H. Suto, M. Iikura, M. Kakurai, J. D. Sedgwick, M. Tsai, and S. J. Galli. 2006. Mast cells enhance T cell activation: importance of mast cell costimulatory molecules and secreted TNF. J. Immunol. 176: 2238-2248.
47. Korkmaz, M. E., A. Oto, Y. Saraçlar, E. Oram, A. Oram, S. Ugurlu, A. Karamehmetoglu, and E. Karaagaoglu. 1991. Levels of IgE in the serum of patients with coronary arterial disease. Int. J. Cardiol. 31: 199-204.
48. Kovanen, P. T., M. Mänttäri, T. Palosuo, V. Manninen, and K. Aho. 1998. Prediction of myocardial infarction in dyslipidemic men by elevated levels of immunoglobulin classes A, E, and G, but not M. Arch. Intern. Med. 158: 1434-1439.
49. -/- mice. J. Clin. Invest. 121: 3564-3577.